Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

PURPOSE: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands...

Descripción completa

Detalles Bibliográficos
Autores principales: Armand, Philippe, Rodig, Scott, Melnichenko, Vladimir, Thieblemont, Catherine, Bouabdallah, Kamal, Tumyan, Gayane, Özcan, Muhit, Portino, Sergio, Fogliatto, Laura, Caballero, Maria D., Walewski, Jan, Gulbas, Zafer, Ribrag, Vincent, Christian, Beth, Perini, Guilherme Fleury, Salles, Gilles, Svoboda, Jakub, Zain, Jasmine, Patel, Sanjay, Chen, Pei-Hsuan, Ligon, Azra H., Ouyang, Jing, Neuberg, Donna, Redd, Robert, Chatterjee, Arkendu, Balakumaran, Arun, Orlowski, Robert, Shipp, Margaret, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881098/
https://www.ncbi.nlm.nih.gov/pubmed/31609651
http://dx.doi.org/10.1200/JCO.19.01389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881098/
https://www.ncbi.nlm.nih.gov/pubmed/31609651
http://dx.doi.org/10.1200/JCO.19.01389

Ejemplares similares